A new meningitis B vaccine could soon be developed after tests revealed that the majority of babies who received a new drug showed a strong immune response.
Results from a study by the pharmaceutical company Novartis, presented at a conference yesterday, showed that it protected against three strains of bacteria that cause meningitis B.
Meningitis B is the most common form of the disease, causing up to 80 per cent of cases in Britain. It is also one of the most deadly, with symptoms that can kill within 24 to 48 hours of onset. However, because of its complex nature,